We are live on ! Find out more
ACM

Aisling Capital Management Portfolio holdings

AUM $476M
1-Year Est. Return 128.63%
This Fund
S&P 500
This Quarter Est. Return
-1.02%
1 Year Est. Return
+128.63%
3 Year Est. Return
+700.94%
5 Year Est. Return
+846.44%
10 Year Est. Return
–
AUM
$234M
AUM Growth
+$103M
Cap. Flow
+$113M
Cap. Flow %
48.47%
Top 10 Hldgs %
95.43%
Holding
14
New
2
Increased
2
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
BBIO icon
BridgeBio Pharma
BBIO
+$105M
2
BCEL
Atreca, Inc. Class A Common Stock
BCEL
+$7M
3
ZSAN
Zosano Pharma Corporation
ZSAN
+$1.45M
4
SYRE icon
Spyre Therapeutics
SYRE
+$486K

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BBIO icon
1
BridgeBio Pharma
BBIO
$15.7B
$103M 44.18%
+3,835,722
New +$105M
EIDX
2
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$34.9M 14.92%
1,123,630
– –
MRKR icon
3
Marker Therapeutics
MRKR
$18.8M
$15.8M 6.77%
200,000
– –
OBSV
4
DELISTED
ObsEva SA Ordinary Shares
OBSV
$15.7M 6.7%
1,386,338
– –
TECX
5
Tectonic Therapeutic
TECX
$529M
$13.2M 5.64%
67,667
– –
BHVN
6
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$12M 5.13%
274,513
– –
SYRE icon
7
Spyre Therapeutics
SYRE
$8.54B
$8.84M 3.78%
51,646
+2,810
+6% +$486K
BCEL
8
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$7.3M 3.12%
+387,653
New +$7M
ZSAN
9
DELISTED
Zosano Pharma Corporation
ZSAN
$6.63M 2.83%
57,959
+12,245
+27% +$1.45M
VIRX
10
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$5.55M 2.37%
217,143
– –
NBRV
11
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$4.4M 1.88%
7,237
– –
RCUS icon
12
Arcus Biosciences
RCUS
$3.55B
$2.65M 1.13%
333,333
– –
VRNA
13
DELISTED
Verona Pharma
VRNA
$2.26M 0.97%
443,596
– –
ACRS icon
14
Aclaris Therapeutics
ACRS
$726M
$1.39M 0.59%
634,455
– –

Similar funds

BF
Brooklyn FI New York $476M AUM 17.97% 1-Year Est. Return
VIA
Vickerman Investment Advisors Spokane, Washington $476M AUM 12.21% 1-Year Est. Return
DE
Devon Energy Houston, Texas $476M AUM
FAM
Frontier Asset Management Sheridan, Wyoming $477M AUM 19.41% 1-Year Est. Return
BHWA
Beacon Harbor Wealth Advisors Virginia Beach, Virginia $477M AUM 49.25% 1-Year Est. Return
AL4A
Accel Leaders 4 Associates Palo Alto, California $475M AUM 391.52% 1-Year Est. Return
LEFP
Leading Edge Financial Planning Knoxville, Tennessee $475M AUM 15.22% 1-Year Est. Return
MVP
Medina Value Partners Los Angeles, California $477M AUM 25.52% 1-Year Est. Return

Aisling Capital Management's Q2 2019 Portfolio in Review

As of Q2 2019, Aisling Capital Management held 14 positions worth $234M, up 78% from $131M the previous quarter. Its ten largest holdings account for 95% of the portfolio.

Aisling Capital Management deployed $113M of net new capital in Q2 2019, opening 2 new positions and adding to 2 existing holdings. Its largest new stake was BridgeBio Pharma: 3,835,722 shares worth $103M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Aisling Capital Management's largest Q2 2019 buy was BridgeBio Pharma: 3,835,722 shares worth $103M.
  • Aisling Capital Management added most to Zosano Pharma Corporation in Q2 2019, an estimated $1.45M increase.
  • Aisling Capital Management's ten largest holdings make up 95% of its $234M portfolio in Q2 2019.
  • Aisling Capital Management opened 2 new positions and closed 0 in Q2 2019.
  • Aisling Capital Management's portfolio value rose 78% quarter-over-quarter to $234M.

Based on Aisling Capital Management's 13F filing for Q2 2019, filed 8 Aug 2019.